Related Experiment Video
Updated: Jun 22, 2026

09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Paratesticular sarcomas in Brazil.
Fernando Korkes1, Marília G Castro, Frederico R Romero
1Division of Urology and Department of Pathology, Medical School of Santa Casa of São Paulo, São Paulo, Brazil. fkorkes@terra.com.br
Urologia Internationalis
|June 10, 2009
Summary
Paratesticular sarcomas are rare but aggressive cancers. This study highlights their high risk of progression and the need for effective adjuvant therapies and long-term follow-up for improved patient survival.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Paratesticular sarcomas are rare malignancies.
- Existing literature primarily consists of isolated case reports.
- Studies on the relative frequency of paratesticular sarcomas are limited.
Purpose of the Study:
- To evaluate the relative frequency of paratesticular sarcomas in the Brazilian population.
- To analyze the clinical characteristics and outcomes of patients with paratesticular sarcomas.
Main Methods:
- Retrospective review of medical records of patients treated for paratesticular sarcomas between 1993 and 2006.
- Data analysis included patient demographics, tumor types, treatment modalities, and survival outcomes.
Main Results:
- Paratesticular sarcomas represented 6.7% of all orchiectomies for testicular malignancies during the study period.
- Common subtypes included rhabdomyosarcoma and leiomyosarcoma.
- Elevated serum lactic dehydrogenase levels were associated with retroperitoneal spread and poorer prognosis.
Conclusions:
- Paratesticular sarcomas carry a high risk of disease progression and systemic relapse, leading to poor prognosis.
- Long-term follow-up is crucial due to the high risk of local recurrence.
- Effective systemic adjuvant therapy is necessary to improve survival rates.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

